Viewing Study NCT03259633


Ignite Creation Date: 2025-12-25 @ 2:49 AM
Ignite Modification Date: 2026-01-06 @ 12:23 AM
Study NCT ID: NCT03259633
Status: APPROVED_FOR_MARKETING
Last Update Posted: 2020-05-01
First Post: 2017-08-21
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1
Sponsor: AstraZeneca
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Eligibility Module Contacts Locations Module